HC21 News

Introducing PuraBond from 3D Matrix

steve newton •

Healthcare21/Aquilant are delighted to introduce PuraBond; a ready-to-use, efficient haemostat for a wide variety of surgical indications. Purabond is a slightly viscous solution of synthetic peptides. Contact between Purabond and positive ions at the bleeding site causes the peptides to form β-sheets, that subsequently form a 3-dimensional scaffold structure(1). Purabond provides a physical barrier to facilitate haemostasis across multiple therapy areas including Cardiac, Surgery, Vascular, ENT & Gynacology. Purabond has also shown to be effective in achieving haemostasis in heparinised patients(2).

(1)PuraBond IFU-004 Rev 1.1(2)Masuhara H, Fujii T, Watanabe Y, Koyama N, Tokuhiro K.Novel infectious agent-free hemostatic material(TDM-621) in cardiovascular surgery. Ann. ThoracCardiovasc Surg. 2012;18(5):444-51. Epub 2012 Sep 14.PMID: P 22986759

HC21 HC21 News Newsletter Quality
Related News
HC21 News

Highlights from the first Paediatric Networking Study Day

The first Paediatric Networking Study Day took place at Edgbaston Cricket Ground in Birmingham, bringing together paediatric theatre professionals for a day of practical learning and open discussion.

HC21 News
HC21 News

Xograph Showcases the Future of Dental Imaging at Snetterton

Xograph Healthcare, part of HC21 UK, was delighted to join the British Superbike Championship at Snetterton alongside colleagues from Planmeca, bringing the latest developments in dental and maxillofacial imaging to visitors.

HC21 News
HC21 News

Innovation in Focus: NanoKnife IRE at King’s College Hospital

Dr Praveen Peddu of King’s College Hospital NHS Foundation Trust has shared his insights into the use of NanoKnife irreversible electroporation (IRE) technology from AngioDynamics International and its expanding application in cancer treatment.

HC21 News
Choose Your Region

This helps us show the right products, services, and contact details.